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Abstract
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active form of vitamin D, exerts potent effects on
several tissues including cells of the immune system, where it affects T cell activation,
differentiation and migration. The circulating, inactive form of vitamin D, 25(OH)D3, is generally
used as an indication of “vitamin D status”. However, utilization of this precursor depends on its
uptake by cells and subsequent conversion by the enzyme 25(OH)D3-1α-hydroxylase (CYP27B1)
into active 1,25(OH)2D3. Using human T cells, we now show that addition of inactive 25(OH)D3
is sufficient to alter T cell responses only when dendritic cells (DCs) are present. Mechanistically,
CYP27B1 is induced in DCs upon maturation with LPS or upon T cell contact resulting in the
generation and release of 1,25(OH)2D3 which subsequently affects T cell responses. In most
tissues, vitamin D binding protein (DBP) acts as a carrier to enhance the utilization of vitamin D.
However, we show that DBP modulates T cell responses by restricting the availability of inactive
25(OH)D3 to DC. These data indicate that the level of “free” 25(OH)D3 available to DCs
determines the inflammatory/regulatory balance of ensuing T cell responses.
Introduction
Besides its longstanding association with calcium regulation and bone density, more
widespread physiological roles for vitamin D are now acknowledged. This is consistent with
the broad distribution of the vitamin D receptor throughout the body1 and the association of
low vitamin D status with numerous diseases in epidemiological studies2. Interestingly, low
vitamin D appears to increase the risk of immune related diseases, including multiple
sclerosis3,4, rheumatoid arthritis (RA)5, type 1 diabetes6 and inflammatory bowel disease7.
Thus, vitamin D appears to have an important immune-regulatory function, which may have
implications for the treatment of many conditions. Consistent with this, vitamin D
supplementation in mouse models of autoimmunity has been demonstrated to have
prophylactic and therapeutic benefit8-13. In-vitro studies have also identified profound
immunological effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active
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form of vitamin D, including inhibited maturation of antigen presenting cells (APCs), which
involves down-regulation of MHC and co-stimulatory molecules14-16. In addition, we and
others have shown that 1,25(OH)2D3 can act directly upon CD4+ T cells, suppressing
cytokines such as IFNγ, IL-17, IL-21 and IL-22, whilst enhancing the regulatory markers
FoxP3, CTLA-4 and IL-1017-21. Although these findings demonstrate the ability of active
1,25(OH)2D3 to directly regulate T cell responses, tight homeostatic mechanisms operate in-
vivo to maintain serum 1,25(OH)2D3 at approximately 0.1nM2, which is somewhat below
the effective concentration of 1,25(OH)2D3 seen in in-vitro studies. It is therefore likely, that
the level of 1,25(OH)2D3 circulating systemically is insufficient to promote anti-
inflammatory effects in-vivo. Furthermore, serum 1,25(OH)2D3 concentration does not tend
to vary greatly between individuals, where even those regarded vitamin D deficient can
show relatively normal 1,25(OH)2D3 levels2. Thus, local production of active 1,25(OH)2D3
from its inactive precursor is likely to be important in order for vitamin D to contribute to
immune regulation in-vivo.
Generation of active vitamin D from its inactive precursor, 25(OH)D3, which is the
predominant form of vitamin D in the circulation, is carried out by the mitochondrial
cytochrome P450 enzyme, 25(OH)D3-1α-hydroxylase (CYP27B1). Whilst most is known
about the activity of this enzyme in the kidneys and bone, wider expression of CYP27B1 is
observed22,23, including its expression by macrophages and DCs24. Indeed, high levels of
1,25(OH)2D3 are found in sarcoidosis patients resulting from CYP27B1 activity in disease-
associated macrophages25. Although the ability of DCs and macrophages to convert
25(OH)D3 to 1,25(OH)2D3 is clear, whether sufficient 1,25(OH)2D3 is generated to
subsequently affect T cell function, is not known. Furthermore, other factors in serum
influence the bioavailability of both 25(OH)D3 and 1,25(OH)2D3 to immune cells. In this
respect vitamin D binding protein (DBP) is of particular interest, since the majority of
25(OH)D3 and 1,25(OH)2D3 is transported by this protein in serum. Indeed, DBP can
facilitate uptake of 25(OH)D3 by epithelial cells of the kidney proximal tubule26, mammary
cells27 and osteoblasts28 that express the DBP transporter proteins megalin and cubulin.
However, the impact of DBP on 25(OH)D3 uptake by immune cells is less clear.
Furthermore, the DBP gene is polymorphic, and three common variants termed GC1S,
GC1F and GC2 are found that appear to have different functional properties, including
varying binding affinities for vitamin D29,30. Interestingly, DBP polymorphisms have also
shown association with inflammatory disorders, including chronic obstructive pulmonary
disease (COPD), tuberculosis (TB), Graves’ disease, RA and diabetes31-33. Thus, 25(OH)D3
status as well as DBP genotype and serum DBP concentration might modulate immune
responses.
We have therefore investigated the effect of local conversion of inactive 25(OH)D3 to active
1,25(OH)2D3 by DCs on subsequent T cell responses. We observed that 1,25(OH)2D3 was
readily produced by DCs upon maturation at a level sufficient to promote an anti-
inflammatory T cell phenotype, exemplified by high CTLA-4 and decreased expression of
IL-17, IFNγ and IL-21. In contrast, T cells alone utilised 25(OH)D3 poorly, consistent with
their limited expression of CYP27B1. The magnitude of the effect resulting from DC
conversion of 25(OH)D3 was dependent on the concentration of available 25(OH)D3 and
was observed within a physiologically relevant range. Importantly, addition of DBP
suppressed the impact of 25(OH)D3 on T cell responses depending upon its variant and
concentration. Together these data suggest that 25(OH)D3 can be locally converted to
1,25(OH)2D3 by DC and that the 1,25(OH)2D3 generated becomes available to T cells. This
indicates that the outcomes of T cell responses to antigen are influenced by the
bioavailability of 25(OH)D3 to DC, which in turn is affected by DBP concentration and
genetic variant.
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Materials and Methods
Cell isolation and cell culture
PBMCs were isolated by Ficoll gradient centrifugation from fresh leukocyte reduction
system cones (provided by The National Blood Service, Birmingham, UK) or from healthy
donors following informed consent in line with institutional and ethical committee approval.
Similarly, samples from RA patients were obtained following informed consent in line with
institutional and ethical committee approval. Isolated cells were washed twice with PBS and
twice with MACS buffer (0.5% BSA, 2mM EDTA in PBS) before re-suspension at 1 ×
108cells/ml for magnetic separation. For CD4+CD25− isolation, CD4+ T cells were first
enriched using a negative selection antibody cocktail (StemCell Technologies). CD25+CD4+
cells were subsequently removed by incubation with anti-CD25 microbeads (Miltenyi
Biotech) and magnetic column separation. CD4+CD25− T cells were re-suspended in
CellGro® SCGM serum free medium supplemented with 50U/ml penicillin and
streptomycin. Monocytes were also isolated by negative selection using an antibody
selection cocktail (StemCell Technologies). For culture to DCs, monocytes were re-
suspended at 2 × 106/ml in RPMI 1640 (Life Technologies/Invitrogen) supplemented with
10% FBS, 50U/ml penicillin and streptomycin, 200μM glutamine (Life Technologies/
Invitrogen) and treated with GM-CSF (800 U/ml, PeproTech) and IL-4 (500U/ml
Peprotech). 1 × 106 cells were plated per well of a 24 well plate. At two days, cells were
supplemented with 500μL medium containing GM-CSF and IL-4. At seven days, DCs were
used in T cell stimulation assays or treated with cytokines: IFNγ (10ng/ml, Peprotech),
IL-1β (10ng/ml, Peprotech), TNFα (100U/ml, Sigma), IL-15 (10ng/ml, R & D Systems)
with or without anti-CD40 (10μg/ml, clone S2C6, Mabtech). When collecting DC culture
supernatants for 1,25(OH)2D3 concentration measurement or supernatant transfer studies,
cells were cultured in CellGro® serum free medium. All cells were cultured at 37°C, 95%
humidity and 5% CO2.
CD4+CD25− T cell stimulation
T cells were cultured with DCs at a 4:1 ratio in the presence of anti-CD3 (clone OKT3,
0.5μg/ml) or stimulated with anti-CD3/anti-CD28 coated beads (Life Technologies/
Invitrogen) at 1:4 bead:cell ratio. All stimulations were prepared in CellGro® SCGM serum
free medium. Where Foxp3 was measured cultures were supplemented with TGFβ (1ng/ml,
R and D Systems) and IL-2 (200U/ml, Peprotech). Where cytokines were measured bead
stimulations were supplemented with IL-1β (10ng/ml, Peprotech), IL-6 (20ng/ml,
Immunotools), IL-23 (10ng/ml, R & D systems), TGFβ (1ng/ml, R & D Systems). Where
indicated, cultures were additionally supplemented with various concentrations of
1,25(OH)2D3 (a gift from Dr. L. Binderup (Leo Pharma, Ballerup, Denmark), 25(OH)D3
(Sigma), purified mixed human vitamin D binding protein (Calbiochem) as indicated or
2.5% plasma. For transwell studies, 24 well, low density 0.4μm inserts (BD Pharmingen)
were used. 2.5 × 105 DCs were plated beneath the insert and 1 × 106 T cells cultured above
the insert. In transwell B, DCs and T cells were co-cultured above the insert at a ratio of 1
DC: 5 T cells. Anti-CD3 was added at 0.5μg/ml.
Flow cytometry
Total CTLA-4 and FoxP3 expression was measured at four days post stimulation. Staining
was performed according to the manufacturer’s instructions using a FoxP3 staining kit
(ebiosciences). For cytokine detection, cells were cultured for five days prior to analysis.
They were then re-stimulated for six hours with PMA (50ng/ml) and ionomycin (1μM) in
the presence of brefeldin A during the last four hours. Cells were subsequently fixed with
3% PFA and permeabilised with 0.1% saponin-PBS. Antibody staining was performed for
30 minutes at room temperature in the presence of 2% goat serum. Following one saponin
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wash and two PBS washes, cells were re-suspended in PBS and analysed by flow cytometry.
For surface stains on live cells, cells were stained on ice in 2% goat serum – PBS for 30
minutes before being collected live or fixed with 1.5% PFA. Cells were acquired on a Dako
cyan flow cytometer and data analysed using FlowJo Software (Tree Star). Total cell counts
were determined by adding a fixed number of counting beads to the sample immediately
prior to collection. The fraction of counting beads collected was then used to convert the
number of CD3+CD4+ T cells collected to the number in the stimulation well, the total
content of which had been collected for analysis. All antibodies were purchased from
ebioscience or BD Biosciences.
Real time PCR analysis
Total RNA was extracted using the TRIzol method (Life Technologies/Invitrogen). 0.5μg
was reverse transcribed with random hexamers using TaqMan reverse transcription reagents
(Life Technologies/Applied Biosystems). Quantitative real-time PCR for CYP27B1 and
18SrRNA was then performed on Applied Biosystems 7500 or 7900 machines using assays
on demand from Applied Biosystems (18S rRNA, 4319413E; CYP27B1, Hs00168017_m1).
Amplification of cDNAs involved incubation at 50°C, 2 min and 95°C, 10 min followed by
40 cycles of 95°C, 15 secs and 60°C, 1 min. CYP27B1 mRNA expression was then
calculated relative to 18SrRNA. For RT PCR, Go Taq Polymerase (Promega) was used with
the following primer sets: Megalin: (Forward) TGGCCATCGATTGGGCTGCTT,
(Reverse) TGGTTGGGTCCCCCTCGCAT; Cubulin: (Forward)
GCGGCTTCACTGCTTCCTA, (Reverse) GAGTGATGGTGTGCCCTTGT; β actin:
(Forward) CATCACCATTGGCAATGAGC, (Reverse) CGATCCACACGGAGTACTTG.
cDNAs were amplified under the following conditions: initial denaturation at 95°C, 3 min
followed by 35 cycles of 95°C, 1 min; 53°C, 45 secs; 72°C, 45 secs and a final extension at
72°C for 5 mins.
Chronic obstructive pulmonary disease (COPD) plasma samples
Plasma samples were taken from the West Midlands COPD collection, which had been set
up to study COPD phenotypes and progression in relation to data from biological samples.
Ethical approval had been granted by the local ethics committee and all patients had given
informed consent. DNA was extracted, quantified and genotyped for SNPs (rs7041 and
rs4588) in the DBP gene that encode variants GC2, GC1F and GC1S, using methods
described previously34.
DBP, 1,25(OH)2D3 and 25(OH)D3 measurements
DBP concentrations were measured by ELISA using a commercially available kit
(Immunodiagnostik, Bensham, Germany). Total 1,25(OH)2D3 was measured by enzyme
immunoassay (University of East and Anglia) and 25(OH)D3 by liquid chromatography-
mass spectrometry (University of East Anglia). When collecting DC and T cell culture
supernatants for 25(OH)D3 and 1,25(OH)2D3 analysis, DCs were re-suspended at 112,500
cells/ml and T cells at 450,000 cells/ml. DCs were matured with LPS (1ug/ml) and T cells
stimulated with anti-CD3/anti-CD28 beads at 1 bead:4 T cells. Cultures were treated with
25(OH)D3 at the indicated concentration with or without DBP (20ug/ml) and incubated for
24 hours. Because vitamin D species were found to degrade to approximately one third of
initial levels before measurement in the absence of DBP (fig. S1) spontaneous degradation
was accounted for by multiplying values of 1,25(OH)2D3 and 25(OH)D3 three fold. DBP
was added at the end of the experiment to all cultures as a protectant and all samples were
stored at −80C before analysis.
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Statistical Analysis
GraphPad Prism3 software was used for statistical analysis. P values were calculated using
non-parametric Wilcoxon or Man-Whitney tests as appropriate. P value ranges are indicated
in figures as follows: * = P<0.05, ** = P<0.01, *** = P<0.001.
Results
Modulation of T cell responses by 25(OH)D3 supplementation requires the presence of
antigen presenting cells
We previously demonstrated that active 1,25(OH)2D3 could directly modify the outcome of
T cell stimulation20. However, since systemic levels of 1,25(OH)2D3 in vivo are potentially
too low to influence T cell responses, we sought to determine whether sufficient
1,25(OH)2D3 could be locally generated from inactive 25(OH)D3 during immune activation.
To test this concept we stimulated CD4+CD25− T cells with mature dendritic cells (mDCs)
in the presence of inactive 25(OH)D3 and measured the effect on responding T cells. As
shown in figure 1A upper panels and table Si, expression of the regulatory protein CTLA-4
and the frequency and absolute number of FoxP3+CTLA-4+ cells was strongly enhanced by
addition of 25(OH)D3. By contrast both the frequency and absolute number of cells
producing inflammatory cytokines was markedly suppressed by 25(OH)D3 (fig. 1B, 1C and
table Si). Importantly, the magnitude of response was similar to 1,25(OH)2D3
supplementation, suggesting that efficient conversion of 25(OH)D3 had occurred. By
contrast, when T cells were stimulated in the absence of APCs, (by using anti-CD3/anti-
CD28 coated beads) we observed only a modest induction of CTLA-4 and little or no
suppression of IFNγ, IL-17 and IL-21 by 25(OH)D3 (fig. 1A, B and C-lower panels and
table Sii). The addition of active 1,25(OH)2D3 to bead-stimulated T cells was however still
effective in modifying CTLA-4 and cytokine expression, indicating that bead stimulated
cells were responsive to 1,25(OH)2D3, in the absence of APCs (fig. 1A, B and C-lower
panels and table Sii). These findings were reproduced using a number of different blood
donors (fig. 1D and E) and indicated that the presence of DCs was required for T cell
responses to be effectively modified by 25(OH)D3.
To test whether the apparent responses to 1,25(OH)2D3 in our DC driven assays might
involve CYP27B1 activity, we treated these stimulations with the CYP27B1 inhibitor,
ketoconazole. This revealed that T cell induction of CTLA-4 upon 25(OH)D3
supplementation was suppressed by ketoconazole supporting a role for CYP27B1 activity
(fig. 2A). Moreover, whilst CYP27B1 mRNA expression is reported in both DCs and T
cells24,35-37 their relative expression has not been formally compared. Thus, to examine
whether the lack of T cell response to 25(OH)D3 in the absence of DCs could relate to levels
of the converting enzyme, we compared CYP27B1 mRNA expression in T cells and DCs
before and after stimulation. This revealed that CYP27B1 mRNA was low in unstimulated T
cells and immature DC (iDC) and that DC maturation with LPS strongly up-regulated
CYP27B1 mRNA (fig. 2B). By contrast, CYP27B1 mRNA in T cells upon stimulation was
significantly lower, supporting the hypothesis that relative to DCs, T cells may be poor
convertors of 25(OH)D3.
We next examined the 25(OH)D3 conversion by mDCs and anti-CD3/CD28 stimulated T
cells by measuring the concentrations of 1,25(OH)2D3 and 25(OH)D3 in the supernatants of
cultures supplemented with 25(OH)D3 for 24 hour. As shown in figure 2C, 1,25(OH)2D3
could be detected in 25(OH)D3 supplemented DC cultures but was below the detection limit
in T cell cultures even at 100nM of 25(OH)D3. Correspondingly, we found that
approximately 30% of available 25(OH)D3 substrate was utilised by mDCs, whilst only 4%
was used by bead stimulated T cells (fig. 2D). These measurements give a useful estimate of
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the relative difference in conversion efficiency by DCs and T cells. Moreover, supernatants
from 25(OH)D3 supplemented DC cultures could induce CTLA-4 expression when
transferred to bead stimulated T cells indicating they contained functionally significant
levels of 1,25(OH)2D3 (fig. 2E). Interestingly, parallel titration studies for 25(OH)D3 and
1,25(OH)2D3 (fig. 2F) revealed similar responses at equivalent concentrations of 25(OH)D3
or 1,25(OH)2D3, thereby reinforcing the idea of effective local conversion by the DC.
Activated T cells can induce CYP27B1 expression and 1,25(OH)2D3 generation in dendritic
cells
Induction of CYP27B1 in response to LPS might be an important mechanism during an
innate immune response to microbes, however we were also interested in whether
1,25(OH)2D3 generation could occur in the absence of this DC maturation signal. To
investigate this, we stimulated T cells using iDCs, which expressed low levels of CYP27B1
mRNA. We observed that, in isolation, iDC were not able to generate sufficient
1,25(OH)2D3 to influence CTLA-4 expression (fig. 3A). Surprisingly, however, following T
cell activation by iDC, changes in CTLA-4, IL-17, IFNγ and IL-21 were found to be
equivalent for both 25(OH)D3 and 1,25(OH)2D3-supplemented stimulations (fig. 3B). This
suggested that efficient 25(OH)D3 conversion still occurred and that during the stimulation
process CYP27B1 was induced. In support of this, we detected high CYP27B1 mRNA
expression in co-cultures of T cells and DCs (fig. 3C). Importantly, CYP27B1 mRNA was
induced only in the presence of both anti-CD3 and T cells, suggesting the need to activate T
cells in order to stimulate CYP27B1 expression. To confirm which cells expressed
CYP27B1, we sorted T cells and DCs after 20 hours of stimulation and measured CYP27B1
mRNA expression in the two fractions. As shown in figure 3C, CYP27B1 mRNA was
highly enriched in the DC fraction indicating that activated T cells could induce CYP27B1
in DCs and again emphasising the relative lack of CYP27B1 expression in T cells. For
comparison, we also tested the ability of APCs other than cultured DC to generate
functionally useful amounts of 1,25(OH)2D3. This showed efficient 25(OH)D3 conversion
when stimulating CD4+ CD25− T cells with purified CD14+ monocytes (fig. S2A) or when
culturing un-manipulated PBMC cultures that contained both CD14+ and CD14− CD11c+
cells with anti-CD3. Furthermore, mononuclear cells isolated from the blood and synovial
fluid of RA patients were also able to convert 25(OH)D3 (fig. S2B).
To distinguish whether cell contact or soluble factors were required for upregulation of
CYP27B1 in iDC driven stimulations, we used a transwell approach. As shown in figure 4A,
CYP27B1 was not induced in iDCs that were separated from anti-CD3 treated T cells
(transwell A). In contrast, soluble factors from wells containing DC and activated T cells
permitted some induction of CYP27B1 in DCs. However, the greatest induction of
CYP27B1 occurred in DCs that were in direct contact with activated T cells (transwell B).
Together these data suggest the importance of surface molecule engagement for CYP27B1
induction in DCs. Consistent with these data, we found that treating DCs with a range of
pro-inflammatory cytokines (IFNγ, IL-1β, TNFα and IL-15) reported to influence
CYP27B1 expression in other cell types38-44, gave a small increase in the expression of
CYP27B1 mRNA (fig. 4B). Similarly, an agonistic antibody to CD40 also promoted
CYP27B1 mRNA expression by the DC. Notably, however, anti-CD40 used in combination
with inflammatory cytokines, resulted in the highest induction (fig. 4B). These treatments
were also found to up-regulate several markers associated with DC maturation (fig.4C).
Thus, together, these data indicate that maturation of DCs during co-culture with activated T
cells permits efficient induction of CYP27B1 in the DC and can be driven by surface
engagement with CD40 and the release of inflammatory cytokines.
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Vitamin D Binding Protein affects T cell responses to dendritic cells
Given that most circulating 25(OH)D3 is bound to vitamin D binding protein (DBP), which
facilitates its uptake by cells, we determined the impact of DBP on T cell responses.
Surprisingly, as shown in figure 5A, addition of purified DBP suppressed T cell responses to
25(OH)D3 in a concentration dependent manner. Interestingly, responses to 1,25(OH)2D3
were much less affected (fig. 5B), suggesting that DBP might preferentially restrict
25(OH)D3 uptake by DCs but have less impact on T cell response to 1,25(OH)2D3.
Consistent with the effect of DBP on T cell phenotype in response to 25(OH)D3, we were
also unable to detect generation of 1,25(OH)2D3 in the presence of DBP (fig. 6A).
Furthermore 25(OH)D3 did not decrease from input levels in these cultures suggesting lack
of availability to DC (fig. 6B). We considered that this inhibition of conversion might be due
to absence of the DBP transporter proteins, megalin or cubulin in DCs. Accordingly, we
could not detect mRNA for megalin or cubulin in DCs in contrast to robust expression in
proximal tubule epithelial cell lines (fig. 6C). Overall, these data suggest a role for DBP in
controlling the availability of 25(OH)D3 for immune regulation.
The three most common DBP variants, GC1S, GC1F and GC2, have different abilities to
bind 25(OH)D3 and 1,25(OH)2D3, their Kd values for 25(OH)D3 being 0.9nM, 1.7nM and
2.8nM respectively, whilst those for 1,25(OH)2D3 are 56nM, 160nM and 240nM
respectively29. We therefore considered the extent to which the immune effects of vitamin D
might be dependent upon DBP variants. We carried out mDC-driven T cell stimulations in
the presence of plasma from individuals with at least one GC2 (low affinity) or one GC1F
(high affinity) allele but not both and compared responses to 25(OH)D3 supplementation.
Plasma samples were taken from a COPD cohort, for which data relating to DBP genotype,
DBP concentration and vitamin D status were already available. The percentage increase in
CTLA-4 expression at either 1nM or 10nM 25(OH)D3 relative to baseline suggested a
weaker response by the high affinity GC1F group (fig. 7A). This observation was consistent
with the stronger 25(OH)D3 binding GC1F variant reducing 25(OH)D3 availability to the
DC compared to the weaker binding GC2 species. Using our GC2 patients who showed the
widest spread of plasma DBP concentration (18-30mg/dl), we also investigated whether
variation in plasma DBP concentration could influence T cell responses to vitamin D. As
shown in figure 7B, DBP concentration inversely correlated with percentage increase in
CTLA-4 expression. Therefore, both DBP binding affinity and level of expression appear to
influence responses to 25(OH)D3 supplementation. Similar trends for DBP variant were
seen for a smaller cohort of healthy individuals (fig. 7C), supporting the possibility that DBP
might influence the availability of 25(OH)D3 to APCs and subsequently 1,25(OH)2D3 to T
cells.
Discussion
A number of studies now support a function for 1,25(OH)2D3 on immune cells such as
monocytes, dendritic cells (DCs) and T cells. Whilst active 1,25(OH)2D3 can directly
influence T cells that express the VDR following activation, it is unlikely that circulating
levels of 1,25(OH)2D3 are sufficient to have such an impact. It is known that antigen
presenting cells (APCs) such as macrophages, monocytes and DC can upregulate the
enzymatic machinery necessary to activate 25(OH)D322,24,42,45. Furthermore, they can
respond to the 1,25(OH)2D3 they generate in an autocrine fashion as indicated by
upregulation of the VDR target genes, cathelicidin and the vitamin D inactivating enzyme,
CYP24A145,46, as well as reduced antigen presentation24 or enhanced anti-microbial
activity42. Thus, APCs may also be able to generate and locally secrete sufficient
1,25(OH)2D3 to directly influence their cognate T cell partners in a paracrine manner.
However, such functional interplay relating to vitamin D metabolism between T cells and
DC has not been extensively studied. We approached this question using a previously
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characterised model where exogenously added 1,25(OH)2D3 was found to have an impact
on T cell responses, resulting in the downregulation of pro-inflammatory cytokines and the
upregulation of the regulatory proteins CTLA-4 and Foxp320. Using these changes in T cell
phenotype as a readout for the availability of 1,25(OH)2D3, we observed that T cell
responses in the presence of 25(OH)D3 were virtually identical to those in the presence of
active 1,25(OH)2D3 as long as DCs were present. The effectiveness of DC as a source of
local 1,25(OH)2D3 correlated with their robust expression of CYP27B1 converting enzyme
upon maturation with LPS. In contrast, T cells alone only modestly expressed this enzyme.
Other studies have reported CYP27B1 expression in T cells35-37. However, whilst these
indicate that T cells could metabolise 25(OH)D3 few functional readouts have so far been
reported. In addition, the concentrations of 25(OH)D3 required for any effects appear to
exceed those expected in-vivo36,37. By contrast, we have shown that the level of CYP27B1
activity in T cells is in fact relatively low compared to DCs and enzyme activity is
insufficient to markedly influence their phenotype as measured by expression of a range of
cytokines and regulatory associated molecules across physiologically relevant
concentrations of 25(OH)D3.
Given the importance of DC as a source of the CYP27B1 converting enzyme, the control of
its expression is of interest. In line with the findings of others24,43, we observed that
bacterial LPS, which signals through TLR4, could induce strong CYP27B1 mRNA
expression in DCs. Induction of CYP27B1 by APCs in response to gram positive TLR2/1
ligands has also been observed42,43,47. Thus, up regulation of CYP27B1 in APCs appears a
central mechanism in vitamin D regulated innate immune responses. In addition to DC
maturation induced by microbial products we observed that during the course of T cell
activation, DCs matured sufficiently to induce functionally significant CYP27B1 expression.
Whilst soluble factors from these cultures or recombinant pro-inflammatory cytokines
permitted detectable CYP27B1 mRNA induction, more effective up-regulation was
observed when DCs were in contact with T cells. Consistent with this observation, agonistic
CD40 antibodies were also effective in stimulating CYP27B1 expression. Combined
treatment with CD40 antibodies and inflammatory cytokines supported the strongest
induction of CYP27B1, similar to the additive effects of cytokines and TLR signalling upon
CYP27B1 expression, as shown in other studies40,42,43. Overall, our study provides further
evidence that cognate interactions occurring between DCs and T cells, including CD40
ligation, promote the induction of CYP27B1 and subsequent metabolism of 25(OH)D3 at a
level that is sufficient to regulate the T cell response. This mechanism could therefore be of
importance in the control of immune responses under non-infectious settings, such as might
occur in autoimmune responses. The data presented here demonstrate CYP27B1 activity in a
range of myeloid cell populations, supporting the view that the expression of CYP27B1
could be a general feature of myeloid cell maturation. Indeed it would be of interest to
ascertain how myeloid cells from different tissues or disease states vary in their levels of
CYP27B1 expression and activity. Furthermore, given that retinal hydrogenase, the enzyme
that activates vitamin A, has been associated with the CD103+ subclass of gut resident
DCs48, variations in CYP27B1 expression with particular DC subclasses would also be of
interest.
A major issue relating to the impact of vitamin D biology on immune cells concerns the
concentration of its various metabolites available under physiological conditions. We have
observed that titrating 25(OH)D3 across physiological levels revealed efficient conversion
and T cell modulation even at concentrations as low as 1nM, although the magnitude of the
response increased towards 100nM suggesting a broad dynamic range. Thus, the outcome of
a T cell response that takes place in the presence of CYP27B1 expressing APCs is likely to
be proportionally sensitive to the available 25(OH)D3. Such data are important, given the
number of studies linking 25(OH)D3 status with autoimmune conditions8,49-52, where
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alteration of the inflammatory/regulatory T cell balance is likely to be involved in the
pathogenesis. At present, total vitamin D is used as an indication of vitamin D status.
However, a number of factors could influence its availability to target cells. An important
candidate is vitamin D binding protein (DBP) since the majority of vitamin D is bound to
this protein in serum. Interestingly, it has recently been suggested that DBP levels can
modify the relationship between vitamin D status and bone mineral density53. Accordingly,
the relationship between vitamin D status and immunological function might also be
influenced by DBP, depending on the ability of immune cells to express DBP transporters.
We observed that addition of DBP strongly suppressed T cell responses to 25(OH)D3,
reducing the magnitude of CTLA-4 induction and inflammatory cytokine suppression. Thus,
whilst DBP may bind to the surfaces of immune cells including monocytes54, neutrophils55
and lymphocytes56,57 it appears that DBP actually restricts availability to DC and
consequently limits T cell responses to 25(OH)D3. This contrasts with the ability of DBP to
promote uptake of 25(OH)D3 by some cell types including kidney cells26, mammary cells27
and osteoblasts28. Interestingly, we did not detect any significant inhibition by DBP on
responses to 1,25(OH)D3, perhaps suggesting that the major effect of DBP is in preventing
uptake of 25(OH)D3 by DCs and that 1,25(OH)2D3 may be less inhibited than 25(OH)D3
due to its lower affinity for DBP. Notably, our findings are consistent with those of Chun et
al., who showed that DBP attenuated monocyte responses to vitamin D metabolites, as
measured by the induction of cathelicidin and CYP24A1 mRNA46. Correale et al suggest
that macrophages and CD4+ T cells can take up DBP58. Whilst their report seemingly
contrasts with our finding that DBP inhibits T cell responses to 25(OH)D3, we would note
that their assay could not distinguish between simple binding of DBP to cells and the
utilisation of transporter proteins to effectively take up DBP. Given the multifunctional
properties of DBP, however, it is likely that differences in DBP binding could have
consequences on T cell behaviour even aside from effects upon 25(OH)D3 metabolism.
Thus, the role of DBP in modifying responses of immune cells to vitamin D metabolites is
worthy of further investigation. In our study we added purified DBP into serum free media,
however, the concentrations of DBP required for effects in-vivo are also likely to be
influenced by other factors in serum. For example, polyunsaturated fatty acids such as
arachidonic acid can bind to DBP and reduce its affinity for both 25(OH)D3 and
1,25(OH)2D359,60. Moreover, the level of DBP within immune environments, such as lymph
nodes is presently unknown. Thus, whilst it is clear that DBP can significantly affect the
availability of 25(OH)D3 to DCs, the level of its impact under physiological conditions is
presently uncertain. A further issue relating to the influence of DBP on T cell responses to
25(OH)D3 is its potential genetic variation, since this can affect its affinity for vitamin D
metabolites29. Our initial data suggest that the stronger binding GC1F genotype more
effectively limits the impact of 25(OH)D3 on CTLA-4 expression compared to the weaker
binding GC2 allele. Chun et al, similarly observed that serum containing the weaker binding
GC2 protein was less inhibitory than that from GC1F individuals in their monocyte assays46.
Thus, together, these studies provide coherent evidence that the availability of 25(OH)D3 to
cells of the immune system can be inhibited by the presence of DBP and that variation in
DBP genotype might further influence the magnitude of inhibition. Furthermore, they raise
the question of the extent to which total 25(OH)D3 accurately reflects the level of 25(OH)D3
that is accessible for immune regulation.
Both environmental and genetic factors impact significantly on the development of
autoimmune conditions. Accordingly, understanding how environmentally regulated
hormones such as vitamin D influence the immune system may be of importance. Low
vitamin D status has been correlated with more active disease in autoimmune models and
population studies, which is in keeping with the observation that the effects of 1,25(OH)2D3
on the adaptive immune response appear to be predominantly immunosuppressive. Of the T
cell markers studied, we have found the up regulation of CTLA-4 to be particularly sensitive
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to 1,25(OH)2D3 which is in keeping with the presence of vitamin D binding sites close to
the CTLA-locus61. Such upregulation of CTLA-4 by 1,25(OH)2D3 is likely to be of
regulatory significance, since we and others have recently identified that CTLA-4 is a direct
effector of T cell suppression that works by downregulating its natural ligands62-65.
Furthermore, it is also clear that 1,25(OH)2D3 can target ligand downregulation on DC
directly22. Thus, control of costimulatory molecules could be a key part of the emerging
immunosuppressive action of 1,25(OH)2D3 on the adaptive immune system8,9.
An increasing body of evidence suggests that vitamin D can have profound effects on the
immune system. The present data reveal that the outcome of T cell activation is strongly
influenced by the availability of the inactive 25(OH)D3 precursor to DCs, since, upon
maturation, these cells upregulate CYP27B1 and generate local 1,25(OH)2D3 at sufficient
level for T cells to respond. Our data further suggest that the availability of 25(OH)D3
depends on both the serum level of inactive 25(OH)D3 and the concentration and genotype
of DBP. Accordingly the level of “free vitamin D” available to the immune system might be
lower than that indicated by standard measures of vitamin D status but could be clinically
relevant in the control of inflammatory disease.
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Figure 1. Inactive 25(OH)D3 promotes an anti-inflammatory phenotype only when T cells are
stimulated by dendritic cells
CD4+CD25− T cells were stimulated with LPS-matured dendritic cells (mDCs) plus anti-
CD3 (top rows) or anti-CD3/CD28 coated beads (beads) (bottom rows) in the presence of
carrier control, 50nM 25(OH)D3 or 10nM 1,25(OH)2D3. Following stimulation, cells were
gated on CD3, and co-stained for A) CTLA-4 and FoxP3, B) IL-21 and IFNγ or C) IL-17
and IFNγ and analysed by flow cytometry. Representative data are shown in A-C and data
from multiple experiments in D and E. Horizontal lines indicate median values. Significance
was tested by a two-tailed Wilcoxon matched pairs test.
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Figure 2. CYP27B1 mRNA expression correlates with 25(OH)D3 conversion activity
A) CD4+CD25− T cells were stimulated for four days with mDCs in the presence or absence
of ketoconazole and total CTLA-4 expression in CD25+ T cells measured by flow
cytometry. B) CYP27B1 mRNA expression was measured in immature (iDCs), LPS-
matured dendritic cells (mDCs) and in un-stimulated and bead stimulated T cells by
quantitative real-time PCR. Levels were normalised to 18S rRNA and are plotted relative to
the unstimulated T cell control. Horizontal lines indicate median expression and significance
was tested by two-tailed Mann Whitney tests. C,D) LPS treated DCs (mDC) and bead
stimulated CD4+CD25− T cells were cultured for 24 hours in the presence of 25(OH)D3 at
indicated concentrations and the concentration of 1,25(OH)2D3 measured at the end of the
assay (C). Dotted lines indicate the sensitivity range of the assay. The percentage of
25(OH)D3 used (D) was calculated by normalising to the level in the medium alone control.
Data are from a single experiment representative of two performed. E) Supernatants from
25(OH)D3-treated mDC or bead stimulated T cell cultures were used to supplement bead-
driven T cell stimulations. CTLA-4 expression was compared to the level in the presence of
control medium. F). CD4+CD25− T cells were stimulated with mature dendritic cells
(mDCs) plus anti-CD3 in the presence of 25(OH)D3 or 1,25(OH)2D3 at the concentrations
shown. Following stimulation, cells were stained for CD3, CTLA-4, IL-17, IFNγ or IL-21
and analysed by flow cytometry. Mean values from five experiments are plotted. Bars
indicate SEM.
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Figure 3. T cell activation promotes CYP27B1 expression in dendritic cells, leading to 25(OH)D3
conversion and an anti-inflammatory T cell phenotype
A) Supernatants from cultures of 25(OH)D3-treated immature DCs (iDCs) or mature DCs
(mDCs) were used to supplement bead-stimulated T cell cultures. At four days, CTLA-4
expression was measured and compared to the level attained when T cells were stimulated in
control medium. B) CD4+CD25− T cells were stimulated with iDCs plus anti-CD3 in the
presence of control, 50nM 25(OH)D3 or 10nM 1,25(OH)2D3. Following stimulation, cells
were stained for CD3, co-stained for CTLA-4, IL-17, IFNγ or IL-21 and measured by flow
cytometry. C) At 20 hours, CYP27B1 mRNA was measured in cultures containing iDCs and
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T cells (+/− anti-CD3) and in purified T cell and DC fractions isolated from these cultures
by cell sorting.
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Figure 4. Contact between activated T cells and immature dendritic cells promotes CYP27B1
upregulation
A) CYP27B1 mRNA expression was measured in immature dendritic cell (iDC) and T cell
cultures set up in combinations as shown. In transwell systems, anti-CD3 was present in
both the top and bottom chambers. B) IDCs were treated with cytokines (IFNγ, IL-1β,
TNFα and IL-15), anti-CD40 alone or antiCD40 with cytokines for 20 hours and their
expression of CYP27B1 monitored by qPCR. Mean expression relative to the level in
untreated DCs is graphed. Error bars indicate SEM. Wilcoxon matched pair tests were used
to test significance. Significant differences (P<0.05) compared to untreated or antiCD40
with cytokines are indicated by stars and crosses respectively. C) Flow cytometric analysis
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of DC markers: CD80, CD86, CD40, HLA-DR, CD1a and CD11c following treatment as
described in B. Data are from one experiment representative of n≥3.
Jeffery et al. Page 19
J Immunol. Author manuscript; available in PMC 2013 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 5. Vitamin D binding protein suppresses 25(OH)D3 driven anti-inflammatory T cell
responses
A) CD4+CD25− T cells were stimulated with mature dendritic cells (mDCs) plus anti-CD3
in the presence of 25(OH)D3 across the range 0-100nM. Stimulations were cross titrated
with purified human vitamin D binding protein (DBP) at the concentrations shown.
Following stimulation, CD3+ cells were analysed for CTLA-4, IL-17, IFNγ and IL-21
expression by flow cytometry. Data are from one experiment representative of two
performed. B) CTLA-4, IL-21, IL-17 and IFNγ expression was measured by flow cytometry
after CD4+CD25− T cells were stimulated with DCs in the presence of 10nM 25(OH)D3 or
10nM 1,25(OH)2D3 and purified human DBP at the concentrations shown.
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Figure 6. Vitamin D binding protein inhibits availability of 25(OH)D3 to DCs
A,B) LPS treated DCs (mDC) or medium alone were incubated for 24 hours in the presence
of 100nM 25(OH)D3 with or without 20μg/ml DBP and the endpoint concentration of
1,25(OH)2D3 measured (A). Dotted lines indicate the sensitivity range of the assay. The
percentage of 25(OH)D3 used during the assay (B) was calculated by normalising to the
level in the medium alone control. C) RT-PCR analysis of megalin, cubulin and β actin
expression in proximal tubule kidney epithelial cells (PTEC), mDCs and iDCs. −RT
indicates without reverse transcriptase. Data are from a single experiment representative of
three performed.
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Figure 7. Vitamin D binding protein genotype influences the magnitude of T cell responses to
25(OH)D3 supplementation
CD4+ CD25− T cells were stimulated with mature dendritic cells for four days at increasing
25(OH)D3 concentrations and supplemented with: 2.5% plasma from COPD patients with at
least one GC2 or one GC1F allele but not both (A and B) or 2.5% plasma from healthy
donors with at least one GC2 or one GC1F allele but not both (C). CTLA-4 expression was
measured by flow cytometry and plotted as percentage increase in expression at the given
25(OH)D3 concentration relative to 0nM 25(OH)D3. Horizontal lines show mean values.
Significance between GC2 and GC1F groups was tested by two-tailed Mann Whitney tests
(A and C) and linear regression analysis used to test association between CTLA-4 induction
and DBP concentration (B).
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